Although the Food and Drug Administration (FDA) has licensed Anakinra for the treatment of rheumatoid arthritis in certain individuals (Mertens and Singh 2009), it is only moderately effective and inferior to TNF-α inhibitors, showing its limited application (Ramírez and Cañete 2018). The gene discussed is TNF; the disease is rheumatoid arthritis.